Walleye Capital
AKBA icon

Walleye Capital’s Akebia Therapeutics AKBA Stock Holding History

Walleye Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-26,200
Closed -$103K – 1746
2019
Q3 		$103K Hold
26,200
– – 0.01% 1429
2019
Q2 		$127K Buy
26,200
+25,900
+8,633% +$147K 0.01% 1144
2019
Q1 		$2K Buy
+300
New +$2.06K ﹤0.01% 1459

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Walleye Capital's AKBA Position: Q4 2025 in Review

Walleye Capital sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 152,953 shares — an estimated $418K sold.

Walleye Capital first reported a position in AKBA in Q2 2019 and held it in 9 quarters. The position peaked at $782K in Q2 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • Walleye Capital reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 152,953 Akebia Therapeutics shares in Q4 2025, an estimated $418K.
  • Walleye Capital first reported a position in Akebia Therapeutics in Q2 2019 and held it in 9 quarters.
  • Walleye Capital's Akebia Therapeutics position peaked at $782K in Q2 2025.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.